Mutant Escherichia coli enterotoxin as a mucosal adjuvant induces specific Th1 responses of CD4+ and CD8+ T cells to nasal killed-bacillus calmette-guerin in mice

Hiroki Takahashi; Keiko Sasaki; Miyuki Takahashi; Naoko Shigemori; Shyunichi Honda; Hideyuki Arimitsu; Sadayuki Ochi; Naoya Ohara; Takao Tsuji

doi:10.1016/j.vaccine.2006.01.060

Mutant Escherichia coli enterotoxin as a mucosal adjuvant induces specific Th1 responses of CD4⁺ and CD8⁺ T cells to nasal killed-bacillus calmette-guerin in mice

Hiroki Takahashi, Keiko Sasaki, Miyuki Takahashi, Naoko Shigemori, Shyunichi Honda, Hideyuki Arimitsu, Sadayuki Ochi, Naoya Ohara, Takao Tsuji

ophthalmology

Research output: Contribution to journal › Article › peer-review

12 Citations (Scopus)

Abstract

On single nasal immunization of mice with killed-bacillus calmette-guerin (BCG) plus a mutant Escherichia coli enterotoxin, delayed-type hypersensitivity was induced and BCG-infection decreased. Spleen cells, particularly CD4 ⁺ T cells among them produced IL-2, IFNγ and TNFα in response to the killed-BCG or purified protein derivatives. CD8⁺ T cells including cytotoxic T lymphocytes produced IFNγ and TNFα. However, both types of T cells reacted a little to Ag85B. The mutant induces cellular immunity to nasal killed-BCG vaccine and decreases BCG-infection. CD4⁺ and CD8⁺ T cells produce cytokines effective for tuberculosis. Although killed-BCG loses some antigens like Ag85B, nasal killed-BCG plus the mutant is useful for tuberculosis.

Original language	English
Pages (from-to)	3591-3598
Number of pages	8
Journal	Vaccine
Volume	24
Issue number	17
DOIs	https://doi.org/10.1016/j.vaccine.2006.01.060
Publication status	Published - 24-04-2006

All Science Journal Classification (ASJC) codes

Molecular Medicine
General Immunology and Microbiology
General Veterinary
Public Health, Environmental and Occupational Health
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.vaccine.2006.01.060

Cite this

@article{0e4f6e73c8eb42a5bc28d6c761640109,

title = "Mutant Escherichia coli enterotoxin as a mucosal adjuvant induces specific Th1 responses of CD4+ and CD8+ T cells to nasal killed-bacillus calmette-guerin in mice",

abstract = "On single nasal immunization of mice with killed-bacillus calmette-guerin (BCG) plus a mutant Escherichia coli enterotoxin, delayed-type hypersensitivity was induced and BCG-infection decreased. Spleen cells, particularly CD4 + T cells among them produced IL-2, IFNγ and TNFα in response to the killed-BCG or purified protein derivatives. CD8+ T cells including cytotoxic T lymphocytes produced IFNγ and TNFα. However, both types of T cells reacted a little to Ag85B. The mutant induces cellular immunity to nasal killed-BCG vaccine and decreases BCG-infection. CD4+ and CD8+ T cells produce cytokines effective for tuberculosis. Although killed-BCG loses some antigens like Ag85B, nasal killed-BCG plus the mutant is useful for tuberculosis.",

author = "Hiroki Takahashi and Keiko Sasaki and Miyuki Takahashi and Naoko Shigemori and Shyunichi Honda and Hideyuki Arimitsu and Sadayuki Ochi and Naoya Ohara and Takao Tsuji",

note = "Funding Information: This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Science, and Culture of Japan, and for the Open Research Center's Project of Fujita Health University from the Ministry of Education, Culture, Sports, Science and Technology of Japan.",

year = "2006",

month = apr,

day = "24",

doi = "10.1016/j.vaccine.2006.01.060",

language = "English",

volume = "24",

pages = "3591--3598",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier Ltd",

number = "17",

}

TY - JOUR

T1 - Mutant Escherichia coli enterotoxin as a mucosal adjuvant induces specific Th1 responses of CD4+ and CD8+ T cells to nasal killed-bacillus calmette-guerin in mice

AU - Takahashi, Hiroki

AU - Sasaki, Keiko

AU - Takahashi, Miyuki

AU - Shigemori, Naoko

AU - Honda, Shyunichi

AU - Arimitsu, Hideyuki

AU - Ochi, Sadayuki

AU - Ohara, Naoya

AU - Tsuji, Takao

N1 - Funding Information: This work was supported by Grants-in-Aid for Scientific Research from the Ministry of Education, Science, and Culture of Japan, and for the Open Research Center's Project of Fujita Health University from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

PY - 2006/4/24

Y1 - 2006/4/24

N2 - On single nasal immunization of mice with killed-bacillus calmette-guerin (BCG) plus a mutant Escherichia coli enterotoxin, delayed-type hypersensitivity was induced and BCG-infection decreased. Spleen cells, particularly CD4 + T cells among them produced IL-2, IFNγ and TNFα in response to the killed-BCG or purified protein derivatives. CD8+ T cells including cytotoxic T lymphocytes produced IFNγ and TNFα. However, both types of T cells reacted a little to Ag85B. The mutant induces cellular immunity to nasal killed-BCG vaccine and decreases BCG-infection. CD4+ and CD8+ T cells produce cytokines effective for tuberculosis. Although killed-BCG loses some antigens like Ag85B, nasal killed-BCG plus the mutant is useful for tuberculosis.

AB - On single nasal immunization of mice with killed-bacillus calmette-guerin (BCG) plus a mutant Escherichia coli enterotoxin, delayed-type hypersensitivity was induced and BCG-infection decreased. Spleen cells, particularly CD4 + T cells among them produced IL-2, IFNγ and TNFα in response to the killed-BCG or purified protein derivatives. CD8+ T cells including cytotoxic T lymphocytes produced IFNγ and TNFα. However, both types of T cells reacted a little to Ag85B. The mutant induces cellular immunity to nasal killed-BCG vaccine and decreases BCG-infection. CD4+ and CD8+ T cells produce cytokines effective for tuberculosis. Although killed-BCG loses some antigens like Ag85B, nasal killed-BCG plus the mutant is useful for tuberculosis.

UR - http://www.scopus.com/inward/record.url?scp=33645219336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645219336&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2006.01.060

DO - 10.1016/j.vaccine.2006.01.060

M3 - Article

C2 - 16556474

AN - SCOPUS:33645219336

SN - 0264-410X

VL - 24

SP - 3591

EP - 3598

JO - Vaccine

JF - Vaccine

IS - 17

ER -